Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia

BACKGROUND: Diagnosis of acute myeloid leukemia (AML) is associated with poor outcome in elderly and unfit patients. Recently, approval of the BCL-2 inhibitor venetoclax (VEN) in combination with hypo-methylating agents (HMA) led to a significant improvement of response rates and survival. Further,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fleischmann, Maximilian, Scholl, Sebastian, Frietsch, Jochen J., Hilgendorf, Inken, Schrenk, Karin, Hammersen, Jakob, Prims, Florian, Thiede, Christian, Hochhaus, Andreas, Schnetzke, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508061/
https://www.ncbi.nlm.nih.gov/pubmed/35099591
http://dx.doi.org/10.1007/s00432-022-03930-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508061/
https://www.ncbi.nlm.nih.gov/pubmed/35099591
http://dx.doi.org/10.1007/s00432-022-03930-5

Ejemplares similares